Role of apolipoprotein e in renal damage protection

Histochemistry and Cell Biology

Volumn 135, Issue 6, 2011, Pages 571-579

  Bonomini, F ^a   Rodella, L F ^a   Moghadasian, M ^b   Lonati, C ^a   Coleman, R ^c   Rezzani, R ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MANITOBA   (Canada)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aging; Apolipoprotein E; Hyperlipidemia; Kidney

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERLIPOPROTEINEMIA TYPE 3; KIDNEY INJURY; MORPHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RENAL PROTECTION;

AGING; ANIMALS; APOLIPOPROTEINS E; HYPERLIPIDEMIAS; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 79960285647     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-011-0815-1     Document Type: Article

References (42)

1. CK Abrass 2004 Cellular lipid metabolism and the role of lipids in progressive renal disease Am J Nephrol 24 46 53 14707435 10.1159/000075925 1:CAS:528:DC%2BD2cXht1ahtL8%3D (Pubitemid 38258276)
2. S Araki DK Moczulski L Hanna LJ Scott JH Warram AS Krolewski 2000 APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies Diabetes 49 2190 2195 11118024 10.2337/diabetes.49.12.2190 1:CAS:528:DC%2BD3cXos1ejsb4%3D
3. ML Blue DL Williams S Zucker SA Khan CB Blum 1983 Apolipoprotein E synthesis in human kidney, adrenal gland, and liver Proc Natl Acad Sci USA 80 283 287 6572003 10.1073/pnas.80.1.283 1:CAS:528:DyaL3sXltFShsA%3D%3D
4. F Bonomini F Filippini T Hayek M Aviram S Keidar LF Rodella R Coleman R Rezzani 2010 Apolipoprotein E and its role in aging and survival Exp Gerontol 45 149 157 19941948 10.1016/j.exger.2009.11.006 1:CAS:528:DC%2BC3cXpslWqtw%3D%3D
5. P Bruneval J Bariéty MF Bélair C Mandet D Heudes A Nicoletti 2002 Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice Nephrol Dial Transplant 17 2099 2107 12454219 10.1093/ndt/17.12.2099 1:CAS:528:DC%2BD38XptlOhsL0%3D (Pubitemid 35446664)
6. A Cases E Coll 2005 Dyslipidemia and the progression of renal disease in chronic renal failure patients Kidney Int Suppl 99 S87 S93 16336584 10.1111/j.1523-1755.2005.09916.x 1:CAS:528:DC%2BD2MXhtlWqtr7J (Pubitemid 44324693)
7. G Chen L Paka Y Kako P Singhal W Duan S Pillarisetti 2001 A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion J Biol Chem 276 49142 49147 11579084 10.1074/jbc.M104879200 1:CAS:528:DC%2BD38Xktlemtg%3D%3D
8. TA Chowdhury PH Dyer S Kumar SP Gibson BR Rowe SJ Davies SM Marshall PJ Morris GV Gill S Feeney P Maxwell D Savage AJ Boulton JA Todd D Dunger AH Barnett SC Bain 1998 Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM Diabetes 47 278 280 9519726 1:CAS:528:DyaK1cXntVOhsA%3D%3D
9. LS Dalrymple GA Kaysen 2008 The effect of lipoproteins on the development and progression of renal disease Am J Nephrol 28 723 731 18434711 10.1159/000127980 1:CAS:528:DC%2BD1cXhtVKmsLnE
10. MD Edo V Andres 2005 Aging, telomeres, and atherosclerosis Cardiovasc Res 66 213 221 15820190 10.1016/j.cardiores.2004.09.007 1:CAS:528: DC%2BD2MXjt1KitLw%3D (Pubitemid 40471036)
11. M Eto K Horita A Morikawa H Nakata M Okada M Saito M Nomura A Abiko Y Iwashima A Ikoda I Makino 1995 Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy Clin Genet 48 288 292 8835322 10.1111/j.1399-0004.1995.tb04111.x 1:STN:280: DyaK28vjt1amtA%3D%3D (Pubitemid 26039097)
12. G Ghiselli EJ Schaefer P Gascon HB Breser Jr 1981 Type III hyperlipoproteinemia associated with apolipoprotein E deficiency Science 214 1239 1241 6795720 10.1126/science.6795720 1:CAS:528:DyaL38Xjt1ykug%3D%3D (Pubitemid 12167328)
13. J Grond JJ Weening 1990 Mesangial cell injury, glomerulosclerosis, and therapeutic intervention Contrib Nephrol 81 229 239 2093502 1:STN:280: DyaK3M3jsFKiuw%3D%3D
14. P Hamet N Thorin-Trescases P Moreau P Dumas BS Tea D de Blois V Kren M Pravenec J Kunes Y Sun J Tremblay 2001 Workshop: excess growth and apoptosis: is hypertension a case of accelerated aging of cardiovascular cells? Hypertension 37 760 766 11230370 1:CAS:528:DC%2BD3MXhvValuro%3D (Pubitemid 32199063)
15. J Herz TE Willnow 1995 Lipoprotein and receptor interactions in vivo Curr Opin Lipidol 6 97 103 7773575 10.1097/00041433-199504000-00007 1:CAS:528:DyaK2MXks12hs7k%3D
16. JW Knowles RL Reddick JC Jennette EG Shesely O Smithies N Maeda 2000 Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment J Clin Invest 105 451 458 10683374 10.1172/JCI8376 1:CAS:528:DC%2BD3cXhtlygu7o%3D (Pubitemid 30127245)
17. SR Lucas VL Costa Silva SM Miraglia F Zaladek Gil 1997 Functional and morphometric evaluation of offspring kidney after intrauterine undernutrition Pediatr Nephrol 11 719 723 9438651 10.1007/s004670050374 1:STN:280: DyaK1c%2FpvFCruw%3D%3D (Pubitemid 27520537)
18. RW Mahley ZS Ji 1999 Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E J Lipid Res 40 1 16 9869645 1:CAS:528:DyaK1MXjsl2hsQ%3D%3D (Pubitemid 29022581)
19. KS Meir E Leitersdorf 2004 Atherosclerosis in the apolipoprotein-E- deficient mouse: a decade of progress Arterioscler Thromb Vasc Biol 24 1006 1014 15087308 10.1161/01.ATV.0000128849.12617.f4 1:CAS:528:DC%2BD2cXkt1Ogsbk%3D (Pubitemid 38737824)
20. M Miyata JD Smith 1996 Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides Nat Genet 14 55 61 8782820 10.1038/ng0996-55 1:CAS:528: DyaK28Xls1SqtbY%3D (Pubitemid 26301547)
21. MH Moghadasian BM McManus LB Nguyen S Shefer M Nadji DV Godin TJ Green J Hill Y Yang CH Scudamore JJ Frohlich 2001 Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans FASEB J 15 14 2623 2630 11726538 10.1096/fj.01-0463com 1:CAS:528:DC%2BD3MXptFamtLw%3D (Pubitemid 33131089)
22. JF Moorhead MK Chan M El-Nahas Z Varghese 1982 Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease Lancet 2 1309 1311 6128601 10.1016/S0140-6736(82)91513-6 1:CAS:528:DyaL3sXhslOiu70%3D (Pubitemid 13240921)
23. P Muntner J Coresh JC Smith J Eckfeldt MJ Klag 2000 Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 293 301 10886574 10.1046/j.1523-1755.2000.00165.x 1:CAS:528:DC%2BD3cXltVyjtbg%3D (Pubitemid 30429874)
24. Y Nakashima AS Plump EW Raines JL Breslow R Ross 1994 ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler Thromb 14 133 140 8274468 1:CAS:528:DyaK2cXivFGlsro%3D
25. A Nicoletti G Caligiuri GK Hansson 2000 Immunomodulation of atherosclerosis: myth and reality J Inter Med 247 397 405 10.1046/j.1365-2796. 2000.00660.x 1:STN:280:DC%2BD3c3isF2jtg%3D%3D (Pubitemid 30180043)
26. T Onuma LM Laffel MC Angelico AS Krolewski 1996 Apolipoprotein E genotypes and risk of diabetic nephropathy J Am Soc Nephrol 7 1075 1078 8829124 1:STN:280:DyaK28vis1yntw%3D%3D (Pubitemid 27465972)
27. L Paka IJ Goldberg JC Obunike SY Choi U Saxena ID Goldberg S Pillarisetti 1999 Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J Biol Chem 274 36403 36408 10593935 10.1074/jbc.274.51.36403 1:CAS:528:DC%2BD3cXit1Sn (Pubitemid 30005246)
28. JF Passos G Saretzki S Ahmed G Nelson T Richter H Peters I Wappler MJ Birket G Harold K Schaeuble MA Birch-Machin TB Kirkwood T von Zglinicki 2007 Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence PLoS Biol 5 e110 17472436 10.1371/journal.pbio. 0050110 (Pubitemid 46790403)
29. LM Pereira DL Querido AC Madeira CA Mandarim-De-Lacerda 2002 Volume-weighted mean glomerular volume in spontaneously hypertensive rats treated with different doses of spironolactone Int Braz J Urol 28 356 362 15748344 (Pubitemid 36329115)
30. AS Plump JD Smith T Hayek K Aalto-Setälä A Walsh JG Verstuyft EM Rubin JL Breslow 1992 Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells Cell 71 343 353 1423598 10.1016/0092-8674(92)90362-G 1:CAS:528: DyaK38XmsV2ns74%3D
31. D Rizzoni S Paiardi L Rodella E Porteri C De Ciuceis R Rezzani GE Boari F Zani M Miclini GA Tiberio SM Giulini CA Rosei R Bianchi EA Rosei 2006 Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism J Clin Endocrinol Metab 91 2638 2642 16608890 10.1210/jc.2006-0101 1:CAS:528:DC%2BD28XntFWgtL8%3D (Pubitemid 44024630)
32. VG Shore B Shore 1973 Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components Biochem 12 502 507 10.1021/bi00727a022 1:CAS:528:DyaE3sXotFaitw%3D%3D
33. JD Stockand SC Sansom 1997 Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease Am J Kidney Dis 29 971 981 9186087 10.1016/S0272-6386(97)90476-5 1:STN:280:DyaK2szivFKisQ%3D%3D (Pubitemid 27251854)
34. K Strehlow S Rotter S Wassmann O Adam C Grohe K Laufs M Bohm G Nickenig 2003 Modulation of antioxidant enzyme expression and function by estrogen Circ Res 93 170 177 12816884 10.1161/01.RES.0000082334.17947.11 1:CAS:528: DC%2BD3sXlsVOnsbc%3D (Pubitemid 36919705)
35. JL Tarry-Adkins SE Ozanne A Norden H Cherif CN Hales 2006 Lower antioxidant capacity and elevated p53 and p21 may be a link between gender disparity in renal telomere shortening, albuminuria, and longevity Am J Physiol Renal Physiol 290 F509 F516 16189290 10.1152/ajprenal.00215.2005 1:CAS:528:DC%2BD28XhsFKiuro%3D (Pubitemid 43725005)
36. ND Vaziri H Kim H Moradi F Farmand K Navab M Navab S Hama AM Fogelman Y Quiroz B Rodriguez-Iturbe 2010 Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice Nephrol Dial Transplant 25 11 3525 3534 20488818 10.1093/ndt/gfq274 1:CAS:528:DC%2BC3cXhtlClurnL
37. T von Zglinicki 2000 Role of oxidative stress in telomere length regulation and replicative senescence Ann NY Acad Sci 908 99 110 10.1111/j.1749-6632.2000.tb06639.x (Pubitemid 30461996)
38. T von Zglinicki 2001 Telomeres and replicative senescence: is it only length that counts? Canc Lett 168 111 116 10.1016/S0304-3835(01)00546-8 (Pubitemid 32524271)
39. T von Zglinicki 2002 Oxidative stress shortens telomeres Trends Biochem Sci 27 339 344 10.1016/S0968-0004(02)02110-2 (Pubitemid 34756516)
40. T von Zglinicki CM Martin-Ruiz 2005 Telomeres as biomarkers for ageing and age-related diseases Curr Mol Med 5 197 203 10.2174/1566524053586545 (Pubitemid 40601647)
41. M Wen S Segerer M Dantas PA Brown KL Hudkins T Goodpaster E Kirk RC LeBoeuf CE Alpers 2002 Renal injury in apolipoprotein E-deficient mice Lab Invest 82 999 1006 12177238 1:CAS:528:DC%2BD38XntVeqs7c%3D
42. E Werle W Fiehn C Hasslacher 1998 Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients Diabetes Care 21 994 998 9614620 10.2337/diacare.21.6.994 1:STN:280:DyaK1c3ns1yjtg%3D%3D (Pubitemid 28488794)